Unicycive Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Unicycive Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2021 to Q3 2024.
  • Unicycive Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $772K, a 8.64% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $772K -$73K -8.64% Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $604K -$319K -34.6% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $686K -$311K -31.2% Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $766K +$614K +404% Dec 31, 2023 10-Q 2024-11-13
Q3 2023 $845K +$654K +342% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $923K +$693K +301% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $997K +$729K +272% Mar 31, 2023 10-Q 2023-05-16
Q4 2022 $152K -$153K -50.2% Dec 31, 2022 10-K 2024-03-28
Q3 2022 $191K Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $230K Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $268K Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $305K Dec 31, 2021 10-K 2023-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.